Hepatitis Monthly

Published by: Kowsar

Sero-Prevalence of Bloodborne Tumor Viruses (HCV, HBV, HTLV-I and KSHV Infections) and Related Risk Factors among Prisoners in Razavi Khorasan Province, Iran, in 2008

Mohammad Khajedaluee 1 , Ali Babaei 2 , Rosita Vakili 3 , Narges Valizade 1 , Fateme Homaei Shandiz 4 , Seyed Moayed Alavian 5 , 6 , Mohsen Seyed Nozadi 1 , Seyed Mohammad Jazayeri 7 and Tahereh Hassannia 8 , *
Authors Information
1 Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 University of Applied Science and Technology, Mashhad Branch Region 6, (Prison Organization), Mashhad, IR Iran
3 Center of Pathological and Medical Diagnostic Services, Iranian Academic Center for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, IR Iran
4 Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
6 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
7 Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
8 Internal Medicine Department, Arash Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: December 01, 2016, 16 (12); e31541
  • Published Online: December 3, 2016
  • Article Type: Research Article
  • Received: July 16, 2015
  • Revised: November 28, 2015
  • Accepted: November 26, 2016
  • DOI: 10.5812/hepatmon.31541

To Cite: Khajedaluee M, Babaei A, Vakili R, Valizade N, Homaei Shandiz F, et al. Sero-Prevalence of Bloodborne Tumor Viruses (HCV, HBV, HTLV-I and KSHV Infections) and Related Risk Factors among Prisoners in Razavi Khorasan Province, Iran, in 2008, Hepat Mon. 2016 ; 16(12):e31541. doi: 10.5812/hepatmon.31541.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Boamah I, Adu-Gyamfi C, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study. BMC Infect Dis. 2008; 8: 33[DOI][PubMed]
  • 2. Saha A, Kaul R, Murakami M, Robertson ES. Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention. Cancer Biol Ther. 2010; 10(10): 961-78[PubMed]
  • 3. Arjmand B, Aghayan SH, Goodarzi P, Farzanehkhah M, Mortazavi SM, Niknam MH, et al. Seroprevalence of human T lymphtropic virus (HTLV) among tissue donors in Iranian tissue bank. Cell Tissue Bank. 2009; 10(3): 247-52[DOI][PubMed]
  • 4. Lam NC, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. Am Fam Physician. 2010; 82(10): 1225-9[PubMed]
  • 5. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006; 28: 112-25[DOI][PubMed]
  • 6. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010; 52(4): 1497-505[DOI][PubMed]
  • 7. Zhang T, Shao X, Chen Y, Zhang T, Minhas V, Wood C, et al. Human herpesvirus 8 seroprevalence, China. Emerg Infect Dis. 2012; 18(1): 150-2[DOI][PubMed]
  • 8. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005; 24(39): 6058-68[DOI][PubMed]
  • 9. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011; 52(3): 172-6[DOI][PubMed]
  • 10. Pebuara 2006. 2010;
  • 11. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol. 2012; 250(1-2): 87-93[DOI][PubMed]
  • 12. Shoeibi A, Etemadi M, Moghaddam Ahmadi A, Amini M, Boostani R. "HTLV-I Infection" Twenty-Year Research in Neurology Department of Mashhad University of Medical Sciences. Iran J Basic Med Sci. 2013; 16(3): 202-7[PubMed]
  • 13. Kalavi K, Moradi A, Tabarraei A. Population-based Seroprevalence of HTLV-I Infection in Golestan Province, South East of Caspian Sea, Iran. Iran J Basic Med Sci. 2013; 16(3): 225-8[PubMed]
  • 14. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003; 23(1): 39-46[DOI][PubMed]
  • 15. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-9[DOI][PubMed]
  • 16. Ahmad B, Ali S, Ali I, Azam S, Bashir S. Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK). Virol J. 2012; 9: 18[DOI][PubMed]
  • 17. Ahmadi Ghezeldasht S, Hassannia T, Rafatpanah H, Hekmat R, Valizadeh N, Ghayour Mobarhan M, et al. Oncogenic Virus Infections in the General Population and End-stage Renal Disease Patients With Special Emphasis on Kaposi's Sarcoma Associated Herpes Virus (KSHV) in Northeast of Iran. Jundishapur J Microbiol. 2015; 8(3)[DOI][PubMed]
  • 18. Ali A, Lal A. False positivity of serological tests for hepatitis C virus. J Ayub Med Coll Abbottabad. 2010; 22(2): 43-5[PubMed]
  • 19. Cobo F. Application of molecular diagnostic techniques for viral testing. Open Virol J. 2012; 6: 104-14[DOI][PubMed]
  • 20. Storch GA. Diagnostic virology. Clin Infect Dis. 2000; 31(3): 739-51[DOI][PubMed]
  • 21. Vazquez-Martinez JL, Coreno-Juarez MO, Montano-Estrada LF, Attlan M, Gomez-Dantes H. Seroprevalence of hepatitis B in pregnant women in Mexico. Salud Publica Mex. 2003; 45(3): 165-70[PubMed]
  • 22. World prison population list 2007. 2007;
  • 23. Report on the global AIDS epidemics. UNAIDS 10th Anniversary Special editio. 2006;
  • 24. Javadi AA, Avijgan M, Hafizi M. Prevalence of HBV and HCV infections and associated risk factors in addict prisoners. Iran J Public Health. 2006; 35(4): 33-6
  • 25. Burek V, Horvat J, Butorac K, Mikulic R. Viral hepatitis B, C and HIV infection in Croatian prisons. Epidemiol Infect. 2010; 138(11): 1610-20[DOI][PubMed]
  • 26. Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. J Infect Dev Ctries. 2010; 4(3): 144-9[PubMed]
  • 27. Nelwan EJ, Van Crevel R, Alisjahbana B, Indrati AK, Dwiyana RF, Nuralam N, et al. Human immunodeficiency virus, hepatitis B and hepatitis C in an Indonesian prison: prevalence, risk factors and implications of HIV screening. Trop Med Int Health. 2010; 15(12): 1491-8[DOI][PubMed]
  • 28. Saiz de la Hoya P, Marco A, Garcia-Guerrero J, Rivera A, Prevalhep study G. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011; 30(7): 857-62[DOI][PubMed]
  • 29. Treso B, Barcsay E, Tarjan A, Horvath G, Dencs A, Hettmann A, et al. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. J Urban Health. 2012; 89(1): 108-16[DOI][PubMed]
  • 30. Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors Correlated With Hepatitis C and B Virus Infections Among Injecting Drug Users in Tehran, IR Iran. Hepat Mon. 2012; 12(1): 23-31[DOI][PubMed]
  • 31. Azarkar Z, Sharifzadeh G. Evaluation of the Prevalence of Hepatitis B, Hepatitis C, and HIV in Inmates with Drug-Related Convictions in Birjand, Iran in 2008. Hepat Mon. 2010; 10(1): 26-30[PubMed]
  • 32. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5)-86[DOI][PubMed]
  • 33. Yasunaga J, Jeang KT. Viral transformation and aneuploidy. Environ Mol Mutagen. 2009; 50(8): 733-40[DOI][PubMed]
  • 34. Coelho HC, de Oliveira SA, Miguel JC, Oliveira Mde L, Figueiredo JF, Perdona GC, et al. Predictive markers for hepatitis C virus infection among Brazilian inmates. Rev Soc Bras Med Trop. 2009; 42(4): 369-72[PubMed]
  • 35. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62(4): 305-13[DOI][PubMed]
  • 36. Jalilvand S, Shoja Z, Mokhtari-Azad T, Nategh R, Gharehbaghian A. Seroprevalence of Human herpesvirus 8 (HHV-8) and incidence of Kaposi's sarcoma in Iran. Infect Agent Cancer. 2011; 6: 5[DOI][PubMed]
  • 37. Fathimoghaddam F, Hedayati-Moghaddam MR, Bidkhori HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran. Hepat Mon. 2011; 11(5): 346-50[PubMed]
  • 38. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in IR IRAN. Gastroenterol Hepatol Bed Bench. 2009; 3(1)
  • 39. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003; 299(5613): 1713-6[DOI][PubMed]
  • 40. Ansaldi F, Comar M, D'Agaro P, Grainfenberghi S, Caimi L, Gargiulo F, et al. Seroprevalence of HTLV-I and HTLV-II infection among immigrants in northern Italy. Eur J Epidemiol. 2003; 18(6): 583-8[PubMed]
  • 41. Catalan-Soares BC, Almeida RT, Carneiro-Proietti AB. Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum and Trypanosoma cruzi among prison inmates at Manhuacu, Minas Gerais State, Brazil. Rev Soc Bras Med Trop. 2000; 33(1): 27-30[PubMed]
  • 42. Fialho M, Messias M, Page-Shafer K, Farre L, Schmalb M, Pedral-Sampaio D, et al. Prevalence and risk of blood-borne and sexually transmitted viral infections in incarcerated youth in Salvador, Brazil: opportunity and obligation for intervention. AIDS Behav. 2008; 12(4 Suppl)-24[DOI][PubMed]
  • 43. Sabbatani S, Giuliani R, Fulgaro C, Paolillo P, Baldi E, Chiodo F. [HIVAb, HCVAb and HBsAg seroprevalence among inmates of the prison of Bologna and the effect of counselling on the compliance of proposed tests]. Epidemiol Prev. 2004; 28(3): 163-8[PubMed]
  • 44. Adoga MP, Banwat EB, Forbi JC, Nimzing L, Pam CR, Gyar SD, et al. Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries. 2009; 3(7): 539-47[PubMed]
  • 45. Anwar MS, Nafees M, Nabi U. Sero-prevalence of HCV and associated infections with HIV and HBV among prisoners in Lahore. Biomedica. 2011; 27(2): 119-1122
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments